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ABSTRACT: Lythrum salicaria herb (LSH) was applied in diarrhea
therapy since ancient times. Despite empirically referenced therapeutic
effects, the bioactivity mechanisms and chemical constituents responsible
for pharmacological activity remain not fully resolved. Taking into
consideration the historical use of LSH in treatment of diarrhea in
humans and farm animals, the aim of the study was to examine in vitro
the influence of LSH and its C-glycosylic ellagitannins on processes
associated with maintaining intestinal epithelium integrity and enter-
opathogenic Escherichia coli (EPEC) growth and adhesion. LSH was not
only inhibiting EPEC growth in a concentration dependent manner but
also its adhesion to IPEC-J2 intestinal epithelial cell monolayers.
Inhibitory activity toward EPEC growth was additionally confirmed ex
vivo in distal colon samples of postweaning piglets. LSH and its
dominating C-glycosylic ellagitannins, castalagin (1), vescalagin (2), and salicarinins A (3) and B (4) were stimulating IPEC-J2
monolayer formation by enhancing claudin 4 production. Parallelly tested gut microbiota metabolites of LSH ellagitannins, urolithin
C (5), urolithin A (6), and its glucuronides (7) were inactive. The activities of LSH and the isolated ellagitannins support its
purported antidiarrheal properties and indicate potential mechanisms responsible for its beneficial influence on the intestinal
epithelium.
Lythraceae, Lythrum salicaria L. (purple loosestrife), is amedicinal plant that was traditionally applied in therapy of
diarrhea and dysentery since ancient times until the early 20th
century. It was used both in traditional and official medical
treatment of diarrhea in humans and farm animals.1,2 Its
antibacterial activities were examined in the mid 20th century,
long before the etiology and pathophysiology of intestinal
infections were fully recognized.3,4 Its effectiveness may be
validated from historical sources reporting its use during
dysentery epidemies in the 18th and 19th centuries and in
military hospitals during World War I.5−8 Despite empirical
therapeutic effects, the mechanisms of action and chemical
constituents responsible for pharmacological activity remain
not fully resolved. The main specialized metabolites of Lythrum
salicaria herb belong to two groups: C-glycosylic ellagitannins
(CGEs) (vescalagin, castalagin, and characteristic for L.
salicaria, dimeric salicarinins A, B, C) and the C-glycosylic
flavonoids (vitexin, orientin, and isoorientin).9 The high
performance liquid chromatography with charged aerosol
detection (UPLC−CAD) analysis have shown that the former
group significantly dominates in polar extracts.10
Diarrhea among farm animals is one of the most important
health conditions, where new preventive and therapeutic
strategies are urgently needed. Postweaning diarrhea in piglets
is a disease which strongly affects pig production. Numerous
stress factors associated with weaning, including social,
environmental, and dietary changes, alter the homeostasis of
the intestinal epithelium and microbiota, rendering young
piglets more inclined to gastrointestinal tract infections. These
changes include disrupted intestinal structure, reduced
digestive and absorptive capacity, damaged intestinal barrier,
loss of microbial diversity, and unbalanced intestinal immune
homeostasis.11 The etiology of postweaning diarrhea is
multifactorial, although it is commonly associated with the
infection with enteropathogenic Escherichia coli (EPEC).
Piglets ingest EPEC found in their environment, which
originates from the gut of animals with EPEC diarrhea, or
subclinical carrier farm animals.12 EPEC adhere to the piglet’s
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small intestinal epithelium using fimbriae and pili and colonize
the surface of the intestinal tract. The release of enterotoxins
causes an increase of water and electrolyte secretion into the
intestinal lumen and alters the functions of enterocytes by
increasing secretion of water and reducing absorption of small
intestinal epithelial cells.13
The rising incidence of antibiotic-resistant bacterial
infections prompted the European Union in 2006 to introduce
a ban on growth-promoting antimicrobials (Regulation 1831/
2003/EC). Nevertheless, the overall use of therapeutic
antimicrobials to treat infections in farm livestock worldwide
remained high. Owing to limitations on antimicrobial use in
veterinary medicine and serious concerns of antibiotic
resistance development and its transfer to human pathogens,
antidiarrheal agents based on novel mechanistic concepts
should be developed. Recent advances in understanding EPEC
microbiology, pathogenesis, ecology, and interactions with the
host become essential for development of novel preventive
and/or therapeutic approaches to fight EPEC-induced
diarrhea.14 The alternative approaches that could contribute
to optimal gut health are a prerequisite to minimize the
prophylactic use of antimicrobials and could lead to improved
productivity of the health and welfare of pigs and sustainability
of pig production.
In recent years, much research was done on alternative
agents and their potential use in the treatment of diarrhea in
piglets.15,16 However, the important aspect associated with the
wide application of natural products in livestock as feed
additives is the cost of its production and availability, which
should be suitable to cover the demands of farm production. L.
salicaria, which widely grows in its natural state in Europe and
is recognized as an invasive plant in North America17 fulfills
these criteria of availability, which makes its eventual
reintroduction as feed additive feasible and associated with
additional economic and ecological benefits.
Taking into consideration the historical use of L. salicaria
herb in treatment of diarrhea in humans and farm animals, this
plant material can be considered as a potential candidate for
development of a new feed additive, which could be applied in
prevention or therapy of diarrhea in postweaning piglets. Thus,
the aim of the study was to examine in vitro the influence of L.
salicaria extract and dominating CGEs on processes associated
with maintaining intestinal epithelium integrity as well as
EPEC growth and adhesion to epithelial cells. Because our
previous study has shown metabolism of L. salicaria CGEs to
urolithins by distal colon microbiota of postweaning piglets,18
these metabolites were included in the studied biological
activity studies.
Table 1. Growth Parameters: Doubling Time (G) and Lag Time (λ) for E. coli Growth Curvesa
G [min] SD μmax λ [min] d SD
E. coli IMT 0147:K89:K88 H2O 29.2 0.6 0.023 72 302 0 3
LSH 20 μg/mL 33.8 0.6 0.020 52 297 −5 6
LSH 50 μg/mL 40.7 0.5 0.017 02 333 32 3
LSH 100 μg/mL 42.8 1.8 0.016 21 400 98 9
LSH 200 μg/mL 41.1 0.6 0.016 86 552 250 13
LSH 500 μg/mL 37.0 1.3 0.018 74 717 415 10
LSH 1000 μg/mL 40.8 1.6 0.017 00 808 507 8
LSH 2000 μg/mL >1440 >1440
DMSO 0.5% 34.1 0.5 0.020 34 300 0 0
1 5 μM 36.8 0.4 0.018 86 317 17 3
1 10 μM 34.3 1.0 0.020 23 310 10 9
1 20 μM 45.6 2.0 0.015 21 380 80 10
1 50 μM 45.3 2.2 0.015 29 502 202 8
1 100 μM 36.6 1.5 0.018 92 647 347 33
1 200 μM 35.9 1.5 0.019 33 722 422 13
1 500 μM >1440 >1440
E. coli DSM 2840 H2O 32.2 1.7 0.021 55 320 0 0
LSH 20 μg/mL 34.6 2.5 0.020 05 312 −8 8
LSH 50 μg/mL 37.3 1.2 0.018 60 332 12 3
LSH 100 μg/mL 38.9 1.4 0.017 82 373 53 6
LSH 200 μg/mL 40.3 0.6 0.017 19 447 127 8
LSH 500 μg/mL 54.1 3.5 0.012 80 593 273 8
LSH 1000 μg/mL 59.9 3.5 0.011 58 890 570 40
LSH 2000 μg/mL >1440 >1440
DMSO 0.5% 31.6 0.8 0.021 90 312 0 3
1 5 μM 33.4 1.3 0.020 73 322 10 3
1 10 μM 34.9 1.5 0.019 87 320 8 5
1 20 μM 38.1 1.1 0.018 19 347 35 6
1 50 μM 43.0 1.3 0.016 11 422 110 8
1 100 μM 42.9 0.4 0.016 16 515 203 5
1 200 μM 56.8 11.8 0.012 20 870 558 50
1 500 μM >1440 >1440
aIMT O147:K89:K88 (Abbottstown) and control strain DSM 2840 were incubated with LSH or castalagin (1). The data are representative for
three independent experiments assayed in triplicate. Growth curves are provided in Figure S2A, Supporting Information.
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■ RESULTS AND DISCUSSION
Infection with EPEC takes place in the small intestine.19 In our
previous studies conducted on gut microbiota of healthy
postweaning piglets, we have shown that ellagitannins present
in L. salicaria extract (LSH) are stable in the gut microbiota of
the jejunum and ileum and that their metabolism begins in the
cecum and continues to the distal colon.18 Thus, it can be
foreseen that, following the oral ingestion of LSH, the
ellagitannins will not be decomposed at this level of the
gastrointestinal tract and will potentially interact with the small
intestine epithelium as well as with pathogenic bacteria.
However, it has to be considered that the ellagitannins of LSH
were shown to be metabolized to urolithins by distal colon
microbiota of piglets. Previous studies on pigs and humans
indicate that urolithins are bioavailable but undergo intensive
enterohepatic circulation, being released with bile, which
results in their presence in the small intestine in the free and
conjugated form.20,21 Taking into consideration the metabolic
fate of LSH, we have included in the study not only LSH and
known ellagitannins castalagin (1), vescalagin (2), salicarinin A
(3), and salicarinin B (4) but also the representative gut
microbiota metabolites, urolithin C (5) and urolithin A (6)
together with a mixture of its phase II conjugates, urolithins A
3-O-glucuronide and 8-O-glucuronide (7). Experiments using
the different extraction procedures indicated that only the
aqueous extract prepared at 40 °C contained 1, 2, 3, and 4,
while extraction at 80 °C led to degradation of dimeric
ellagitannins 3 and 4. Owing to the high polarity of the
ellagitannins, they were present only in small amounts in the
70% EtOH extract (Figure S7, Supporting Information).
Inhibition of E. coli growth by LSH was determined for two
strains, the enteropathogenic strain E. coli Abbotstown
O147:K89:K88 (ECA) and an E. coli DSM 2840 control
strain (DSM). The growth inhibition of both strains, seen as an
increase in lag time and an increase in doubling time, were
observed (Table 1, Figure S3A, Supporting Information). The
inhibition was concentration-dependent at a range of 20−2000
μg/mL. There were some differences in the level of inhibition
between the two E. coli strains at certain concentrations, but
for both strains, the minimal inhibitory concentration (MIC)
was determined at the level of 2000 μg/mL. Similar results of
inhibition growth were observed for 1 (Table 1, Figure S3A,
Supporting Information) with an MIC value of 500 μM
associated with high turbidity of tested samples. To determine
whether in samples of 2000 μg/mL of LSH and 500 μM of 1 E.
coli growth was observed, after a 24 h measurement, 100 μL of
well content was seeded on a brain heart infusion (BHI) agar
plate and incubated at 37 °C for 48 h. No growth of E. coli
colonies was observed. The experiments conducted for gut
microbiota metabolites 5, 6, and 7 showed no inhibition of
bacterial growth at concentration range 20−500 μM (Figure
S3B, Supporting Information). In contrast to tested LSH and
1, significant differences in susceptibility between ECA and
DSM strains toward the positive control (ciprofloxacin) were
observed (Figure S3C, Supporting Information), the former
being far more resistant to chemotherapeutics with an MIC of
100 ng/mL.
EPEC spreads among farm animals via fecal−oral trans-
mission.22,23 To check if LSH remains active against EPEC
growth in the presence of gut microbiota, a model of ex vivo
distal colon microbiota infection with the ECA strain was
developed. In order to selectively monitor the strain growth,
the DNA coding fae fimbriae was quantified using qPCR at the
chosen time points. First, the model was developed and
validated (Figure S4, Supporting Information). It was shown
that the growth curves of ECA are dependent on the size of
initial inoculum and no bacteria carrying fae gene are initially
present in piglet feces. For further studies, the 104 CFU/mL
inoculum was chosen. The studies on pure ECA cultures
confirmed the concentration-dependent inhibition of bacteria
growth observed in an experiment using the turbidimetric
method; however, at 2000 μg/mL LSH, although significantly
attenuated, growth was still observed (Figure 1). As expected,
the ECA growth in fecal samples was significantly weakened; at
the same time, the inhibitory activity of LSH was stronger, and
at 2000 μg/mL, no fae gene was detected. This implicates the
complete eradication of the inoculated E. coli strain from fecal
samples (Figure 1).
The cytotoxicity tests of LSH and 1 showed no negative
influence on viability of IPEC-J2 (Figure S5, Supporting
Information). The cell monolayers were incubated with LSH
or 1 for 24 h and washed prior to infection with the ECA
strain, to avoid direct impact of tested principles on bacterial
growth. Treatment of IPEC-J2 cells with LSH at the
concentration of 100 μg/mL resulted in statistically significant
inhibition of EPEC adhesion by 20.4 ± 6.3%. A similar effect
was observed for 1, which at a concentration of 100 μM
inhibited EPEC adhesion by 37.7 ± 2.4% (Figure 2).
Metabolites 5, 6, and 7 were inactive (data not shown).
Transepithelial electrical resistance (TEER) measurement is
used to assess the barrier function of epithelial cell monolayers
cultured on inserts. TEER measurement is applied to
determine permeability changes, being a consequence of
tight junction protein production/degradation dynamics and
the membrane physical perturbations induced by pharmaco-
logical or mechanistic agents.24 The IPEC-J2 cell monolayers
were treated with LSH or pure compounds when the TEER
values reached 1 kΩ cm2. The addition of culture medium
containing LSH resulted in significant stimulation of
Figure 1. Growth curves of enteropathogenic E. coli strain, IMT
O147:K89:K88, incubated with LSH in piglet fecal samples
monitored by qPCR determination of fimbrial fae gene copies. pc =
pure E. coli culture (BHI), and M = fecal sample. The data are
representative for two independent experiments assayed in duplicate.
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monolayer formation determined as increased TEER during
subsequent 6 day treatment including 2 times medium
exchange (Figure 3A). Similar effects were observed for
isolated ellagitannins, monomeric 1 and 2 and dimeric 3 and 4,
at a concentration of 20 μM (Figures 3B,C). At the end of the
experiment, the cells were lysed and the amount of TJ proteins
was determined using Western blot. An increase in claudin 4
and ZO-1 protein production was observed for LSH, while
only dimeric ellagitannins 3 and 4 showed activity toward
claudin 4 induction (Figures 3D−F, Table S1, Supporting
Information). Moreover, Spearman correlation analysis
performed for each examined well indicated statistically
significant correlation between determined TEER values and
claudin 4 levels (Table S2, Supporting Information). The
qPCR analysis conducted for cells treated with LSH at 500 μg/
mL also indicated a significant increase of mRNA expression
for claudin 4 and ZO-1 (Figure 4). Metabolites 5, 6, and 7 had
no effect on IPEC-J2 cell monolayer development (Figure S6,
Supporting Information).
Postweaning diarrhea in piglets is often associated with
proliferation of one or more strains of enteropathogenic EPEC
in the gastrointestinal tract. EPEC colonizes the small intestine
by binding to the apical side of enterocytes via F4 (or K88)
fimbriae which interact with glycoprotein receptors. The
attached bacteria then secrete different enterotoxins such as
the heat-labile toxin (LT) or heat-stable toxins a and b (STa
and STb). These toxins trigger an intracellular signaling
cascade resulting in inflammation and the hypersecretion of
electrolytes and water into the intestinal lumen, leading to
watery diarrhea.25
LSH clearly inhibited the growth of two different E. coli
strains in a concentration dependent manner, reaching an MIC
at 2000 μg/mL. There were however only minor differences in
activity between ECA and control DSM strains, which
indicates a lack of strain-specificity in the antimicrobial activity
of the extracts. The experiments conducted on the C-glycosylic
ellagitannin 1 confirmed that this compound contributes to the
inhibition of bacterial growth. Previous studies on LSH
regarding its antibacterial activity toward E. coli have shown
no effects to moderate effects. The studies showing no activity
of LSH were conducted for MeOH extracts26 or EtOH(aq)
extracts prepared using a Soxhlet apparatus.27 The determined
activity of 1 indicates that ellagitannins are the compounds
responsible for inhibition of E. coli growth by LSH. They are
highly polar and heat liable compounds, especially dimeric 2
and 3, which could explain the lack of activity determined
during previous examinations. The aqueous extract was
prepared at temperatures not exceeding 40 °C. This prevented
ellagitannin hydrolysis and resulted in inhibitory activity
toward E. coli growth. The results obtained for 1 are congruent
with previous studies, which showed its exceptional activity
among other examined ellagitannins and condensed tannins
toward growth of different E. coli strains (including clinical
EPEC isolates) with a mean MIC of 705 ± 169 μM.28 The
broader studies including a more diverse array of polyphenols
and different bacteria groups showed structure dependent
activities of polyphenols and that the Enterobacteriaceae is the
least susceptible group of bacteria. However, 1 was shown to
be exceptionally active in E. coli growth inhibition with an MIC
value of 533 μM.29,30 Structure−activity studies showed that
the pyrogallol-type structural element is crucial for the
antimicrobial activity of tannins; however, the exact mecha-
nism responsible for growth inhibition has not yet been
determined.29,31 In the case of E. coli, it can be hypothesized
that the iron chelating properties of ellagitannins may be
responsible for growth inhibition. The C-glycosylic ellagitan-
nins were previously shown to form navy complexes with Fe3+
ions.9 Ferric ions are necessary for E. coli growth, and their
chelation is a known mechanism of antibacterial activity of
lactoferrin present in human milk or released by infiltrating
leucocytes.31 This hypothesis requires further mechanistic
studies to be fully verified.
The antimicrobial activity of LSH was further confirmed in
an ex vivo model with distal colon samples inoculated with the
ECA strain. The addition of LSH at a concentration of 2000
μg/mL resulted in complete inhibition of ECA growth in distal
colon samples. This observation reveals that the presence of
the microbiota in colon samples does not affect the inhibitory
properties of LSH by inactivation of its active principles under
the conditions of the ex vivo assay. After we take into
consideration that E. coli spreads among piglets via fecal−oral
transmission, the potential activity of LSH to decrease EPEC
fecal shedding can be considered to be of epidemiological
significance.22,23
Adhesion to the intestinal epithelium is a prerequisite step
for many pathogenic bacteria, and thus, the influence of LSH
on this process was examined. The pretreatment of IPEC-J2
monolayers with LSH and 1 resulted in a significant inhibition
of bacterial adhesion despite the fact that the tested principles
were removed from the culture medium before infection.
Based on the commonly attributed nonspecific tannin−protein
interactions, it could be hypothesized that the interaction of E.
coli with epithelial cells was prevented by the tannin molecules
randomly attached to the cell surface proteins. However, a
study conducted by Tang et al. (2003)32 clearly showed that
nonspecific protein binding in the case of CGEs is not strongly
marked, in contrast to other ellagitannins, condensed tannins,
and gallotannins. In CGEs, the intergalloyl linkages severely
restrict the flexibility of galloyl groups and reduce the
hydrophobic interactions. In addition, the specificity of the
biological activities of CGEs were confirmed not only in
enzymatic studies, but also in in vitro experiments on cell
models.33−36 The characteristic feature of LSH is that, in
comparison to other ellagitannin-containing plant materials
with potential application in postweaning diarrhea (Castanea
sativa, Quercus sp., Rhus sp.), it strictly contains only
ellagitannnins of C-glycosylic nature.9,37−39 After we take
into consideration the crucial role of actin polymerization
Figure 2. Influence of LSH and castalagin (1) on the adhesion of the
enteropathogenic E. coli strain O147:K89:K88 to IPEC-J2 cell
monolayers. Data are expressed as mean ± SD of three separate
experiments conducted in triplicate. Statistical significance *p < 0.05,
**p < 0.01 decrease versus PBS control (Dunnett’s posthoc test).
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beneath the attached bacteria in the adhesion of EPEC to
epithelial cells,40 it can be hypothesized that previously
determined specific activity of CGEs to bind actin filaments
without any perturbation of the microtubule network41 may
contribute to the observed inhibition of bacterial adhesion of
LSH and 1. The proposed mechanism, however, requires
further verification. Until now, only a few feed additives such as
extracts from wheat bran, casein glycomacropeptide, mannan-
oligosaccharides, locust bean extract, and Aspergillus oryzae
fermentation product or autolyzed yeast product were shown
to reduce EPEC attachment to IPEC-J2 cells.42,43 However,
due to a high composition heterogeneity, none of them could
serve as a referenced positive control in the adhesion
experiments.
To evaluate the potential long-term impact of LSH on the
epithelial cell monolayer condition, cultures of IPEC-J2 cells
were grown on inserts. The addition of LSH to the apical side
stimulated monolayer formation (determined as increase in
TEER), while experiments conducted on isolated CGEs
confirmed their contribution to the augmented monolayer
development. The analysis of TJ protein levels at the end of
conducted experiments indicated that the stimulation of
claudin 4 mRNA expression and protein production
contributes to the observed increase in TEER values. Although
all tested ellagitannins stimulated monolayer formation,
Figure 3. (A−C) Changes in TEER of IPEC-J2 cell monolayers incubated from day 7 with medium containing LSH at concentrations of 100 and
500 μg/mL, castalagin (1), vescalagin (2), salicarinin A (3), or salicarinin B (4) at a 20 μM concentration. The data are representative for three
independent experiments assayed in triplicate (LSH and 1) or one experiment assayed in triplicate (2, 3, and 4). (D−F) Respective changes in tight
junction protein (TJ) expression using Western blot performed at day 13. Western blots and calculations are provided in Table S1 (Supporting
Information). Spearman correlation analysis between TEER and TJ levels are provided in Table S2 (Supporting Information).
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dimeric 3 and 4 enhanced only the production of claudin 4.
Elevated levels of ZO-1 mRNA expression and protein
production were observed for LSH, but this effect was less
significant and could not be attributed to any of the tested
ellagitannins. These observations indicate that other com-
pounds present in the extract could contribute to LSH activity
toward IPEC-J2 monolayers, such as C-glycosylic flavonoids,
anthocyanins, or polysaccharides,1 especially in terms of ZO-1
stimulation. This is the first description of compounds that
stimulate IPEC-J2 monolayer formation.
The metabolites formed from ellagitannins in the distal
colon by the gut microbiota in post weaning piglets18
(potentially present in the small intestine due to enterohepatic
circulation20) do not show inhibitory activity neither toward
E.coli growth nor toward its adhesion to the epithelial cell
surface. Although 6 was previously shown in vivo and in vitro
to significantly enhance gut barrier function and inhibit
unwarranted inflammation44 as well as restore LPS-triggered
decrease in ZO-1 production in Caco-2 cells,45 in the current
study no activity toward stimulation of IPEC-J2 cell monolayer
formation was observed (Figure S6, Supporting Information).
These data permit us to hypothesize that the beneficial activity
of urolithins toward the intestinal barrier could be of
significance mostly due to their anti-inflammatory properties,
due to the lack of immune responsiveness of IPEC-J2 cells to
LPS (neither decrease in TEER nor induction of TNF-α
mRNA expression was observed for cells stimulated with 1 μg/
mL LPS, data not shown).
Until now, studies of L. salicaria herb on antidiarrheal
activity referred to its impact in vivo and ex vivo on intestine
contractility gave contradictory results.3,46−48 Experiments
conducted on weaned rabbits fed with a diet supplemented
with 0.2 and 0.4% of ground herb indicated that LSH does not
cause significant adverse effects in terms of performance, blood
parameters, and nutrient digestibility as well as gut microbiota
community composition and metabolism.49 Despite the
antimicrobial activity for LSH and 1 toward E. coli, our
previous study conducted ex vivo on gut microbiota of healthy
postweaning piglets indicated no negative impact on the cecal
or distal colon microbiota diversity and metabolism.18
The observed activities of LSH and isolated ellagitannins
support its traditionally attributed antidiarrheal properties and
indicate potential mechanisms responsible for its beneficial
influence on the condition of the intestinal epithelium. It was
clearly shown that LSH inhibits EPEC growth not only in pure
cultures but also ex vivo in fecal samples that could be of
significance in terms of prevention of fecal shedding of
infecting bacteria. The extract also prevented the adhesion of
the E. coli enteropathogenic strain and stimulated the
formation of cell monolayers by enhancement of TJ protein
production. The experiments conducted for the isolated
compounds permit attribution of these effects to the presence
of CGEs. The high polarity and susceptibility to decom-
position at high temperatures of these compounds implicate
the use of polar solvents and low temperatures for obtaining
preparations applied in further in vitro and in vivo studies.
Comparative studies conducted for urolithins, the gut
microbiota metabolites of L. salicaria ellagitannins, indicate
that these compounds do not influence the applied processes.
However, they do not exclude their anti-inflammatory
activities, which could be of significance in infection-triggered
intestinal inflammation. After we take into consideration the
complexity of the biological effects depending on extract
composition, metabolism, and distribution of its constituents,
it is necessary to confirm the observed effects in further in vivo
studies.
■ EXPERIMENTAL SECTION
Plant Material Collection. Lythrum salicaria L. herb was
collected in August 2016 in Umer, sẃiet̨okrzyskie region, Poland
(50°59′16.7″N 20°35′37.5″E), from its natural habitat. The plant was
identified by Dr. Jakub Piwowarski in the Department of
Pharmacognosy and Molecular Basis of Phytotherapy, Medical
University of Warsaw, based on morphological characters according
to Rutkowski, 1998 (klucz), where a voucher specimen LSH2016U is
deposited.
Extract and Compounds. The LSH was prepared and stand-
ardized as previously described.9,10 Plant material was dried in the
shade and cut into pieces. A portion (100 g) was with distilled water
(3 × 1L, 30 min each) at 40 °C using an ultrasonic bath. The extract
was filtered, combined, and freeze-dried. The amount of crude dry
extract was 21.0 g. The ellagitannins, castalagin (1), vescalagin (2),
salicarinin A (3), and salicarinin B (4), were isolated from L. salicaria
aqueous extract.9 The content of compounds in the extract was
determined using a published method.10 LSH contained 33.1 ± 1.5
mg/g of 1, 47.5 ± 2.4 mg/g of 2, 52.1 ± 2.5 mg/g of 3, and 45.0 ± 2.3
mg/g of 4. Urolithins C and A (5 and 6, respectively) were
synthesized according to Bialonska et al.;50 phase II conjugate mixture
of urolithin A 3-O- and 8-O-glucuronides (7) was isolated from
human urine according to Piwowarski et al.51 The ultra high
performance liquid chromatography−diode array detector−tandem
mass spectrometry (UPLC−DAD−MS) chromatogram of LSH and
structures of tested compounds are provided in Figures S1 and S2
(Supporting Information).
Examination of the Stability of Tannins Stability. Plant
material (10 g) was extracted once with 10 mL of distilled water or
70% EtOH/water (v/v) at 40 °C for 30 min using an ultrasonic bath
Figure 4. Expression of mRNA at day 13 for claudin 3 and 4 and zona occludens-1 in IPEC-J2 cell monolayers incubated from day 7 with LSH at
500 μg/mL. Data are expressed as mean ± SD. Statistical significance #p < 0.05, ##p < 0.01 increase versus PBS control (Mann−Whitney test).
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or at 80 °C for 24 h. The extracts were filtered and analyzed using
UPLC−DAD.
Inhibition of E. coli Growth. The enterotoxigenic E. coli strain
Abbotstown, serotype O147:K89:K88 (ECA), was used throughout
the experiments as representative strain for enteropathogenic E. coli
(EPEC); E. coli DSM 2840 strain (DSM) (DSMZ, Braunschweig,
Germany) was used as a nonpathogenic, nonfimbriated control strain.
Bacteria were obtained from cryopreservation and grown in BHI
medium (Roth, Karlsruhe, Germany) under constant shaking at 37
°C, starting 2 days prior to experimentation. Twice a day, 10 μL of
bacterial solution was transferred to 10 mL of new, sterile BHI
medium. Double concentrated BHI medium was dispensed into
microtiter plates at 100 μL per well. LSH stock solution was prepared
in deionized water, 1, 5, 6, and 7 stock solutions were prepared in
DMSO. The solutions were sterilized by filtration through 0.22 μm
PVDF syringe filters. Ciprofloxacin (Polpharma, Warsaw, Poland) was
applied as a positive control. Appropriately diluted extract/compound
stock solution (20 μL) was added to each well to achieve the
designated concentration. The E. coli strains ECA and DSM were
added to each well yielding a final concentration of 104 E. coli CFU/
mL. Plates were sealed with adhesive film to provide anaerobic
conditions and cultured at 37 °C in a microplate reader (Tecan
Infinite200Pro, Germany). The turbidity (OD690 nm) was recorded
every 5 min for 24 h. For determination of lag time (λ [min]), the lag-
exponential (λL) method was used.
52
Inhibition of E. coli Growth in Fecal Microbiota Cultures.
Feces obtained from 6−8-week-old piglets by rectal stimulation were
immediately transported to an anaerobic chamber (BACTRON
anaerobic chamber, model BACTRON300-2 6.0A, Sheldon Manu-
facturing, Inc., Cornelius, Oregon, USA) and mixed with PBS 1:5 (w/
v) to create a fecal slurry (FS). LSH was dissolved in deionized water
and sterilized by filtration through 0.22 μm PVDF syringe filters. FS
(4.5 mL) was mixed with 5 mL of BHI, and 0.5 mL of LSH solution
was added to achieve the appropriate concentration. For determi-
nation of EPEC growth in microbiota cultures, E. coli IMT
0147:K89:K88 (ECA) strain was added to cultures to achieve
concentrations of 106, 105, 104, and 103 CFU/mL. For determination
of EPEC growth in the presence of LSH, a concentration of 104 CFU/
mL of the ECA strain was chosen. To exclude the presence of EPEC
in feces, FS cultures without inoculation with ECA strain were
performed. For comparison, the influence of LSH on ECA growth in
pure cultures without FS was tested in parallel. Cultures were
performed in an anaerobic chamber incubator at 37 °C. A sample (1
mL) for each time point (0, 1, 2, 4, 8, and 24 h) was taken and
immediately frozen at −30 °C for further analysis. After they were
thawed, samples were centrifuged at 4 °C for 10 min at 21 000 g, the
supernatant was removed, and the pellet was subjected to DNA
isolation. DNA from culture pellets was extracted using the QIAamp
DNA Stool Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. The amount of DNA was quantified using
NanoDrop fluorospectrometer ND-3300 (Peqlab, Erlangen, Ger-
many).
Real Time qPCR. The growth of the ECA strain in microbiota
cultures was monitored through determination of K88 (fae) fimbrial
operon copies. The DNA was quantified by Brilliant II SYBR Green
QPCR Kit (Agilent Technologies, Palo Alto, CA, USA) using Aria Mx
Real-Time PCR system (Agilent Technologies). For the qPCR
experiments, primers against the sequence coding K88 fimbriae were
used (sense = 5′-GTTGGTACAGGTCTTAATGG-3′, antisense =
5′-GAATCTGTCCGAGAATATCA-3′). The cycling conditions were
95 °C for 10 min followed by 40 cycles of denaturing at 95 °C for 15 s
and annealing/extension for 1 min at 55 °C. The ECA strain growth
was expressed as the number of fae copies/ng DNA against calibration
samples with known copy numbers.
IPEC-J2 Cell Culture. The IPEC-J2 cell line (ACC 701) was
obtained from DSMZ (Braunschweig, Germany) and grown in
Dulbecco’s MEM/Ham’s F-12 (DMEM, Biochrom GmbH, Berlin,
Germany) medium supplemented with 10% FBS, with addition of
penicillin (100 IU/mL) and streptomycin 100 mg/mL (Biochrom
GmbH, Berlin, Germany), at 37 °C in 5% CO2. The cells from
passages 42−60 were used for the experiments. The cell culture was
routinely tested to be free of Mycoplasma spp. contamination.
IPEC-J2 Cell Viability. The IPEC-J2 cells were seeded in 24-well
plates at a density of 105 cells/well and maintained in the culture
plates for 7 days at 37 °C with 5% CO2, with a medium change every
second day. To assess the impact on viability, cells were incubated
with increasing concentrations of LSH (20, 100, and 500 μg/mL) and
1 (5, 20, and 100 μM). After 24 h of incubation, the cells were washed
twice with PBS, trypsinized, stained with propidium iodide (PI), and
analyzed using FACS (MACSQuant Analyze, Miltenyi Biotec,
Bergisch Gladbach, Germany). The viability was assessed as the
percentage of PI(−) cells.
IPEC-J2 Adhesion Studies. The IPEC-J2 cells were seeded in 24-
well plates at a density of 105 cells/well and maintained in the cell
culture plates during 7 days at 37 °C with 5% CO2 and a medium
change every second day. On day 8, the medium was removed, cells
were washed twice with warm PBS, and medium containing LSH or
tested compounds at designated concentration was added to each
well. On day 9, the medium was removed, the cells were washed twice
with warm PBS to remove LSH, 1, and antibiotics, and fresh
antibiotic-free medium was added. The cells were infected with the
ECA strain using a multiplicity of infection (MOI) of 100 as described
previously,53 equivalent to 1 × 107 bacteria per well. A nonfimbriated
E. coli strain DSM 2840 (DSM) was used as a negative, nonadherent
control. Staining and detection of E. coli strains were performed using
fluorescent stain 5,6-carboxymethyl fluorescein diacetate succinimidyl
ester (CFDA-SE) (Sigma-Aldrich, Steinheim, Germany). Bacteria
were incubated with 1 mM CFDA-SE at 37 °C for 120 min and then
centrifuged (13 000 g, 4 min, 4 °C), resuspended in PBS, counted,
and used for infection. After 45 min of incubation with stained
bacteria, the cells were washed with PBS (three times) to remove
nonadherent bacteria, trypsinized with trypsin/EDTA (Biochrom AG,
Berlin, Germany), suspended in 1 mL of cell medium, and centrifuged
at 4000 g for 5 min at 4 °C. The pellet was resuspended in 300 μL of
antibiotic free medium. Flow cytometric measurement was carried out
using MACSQuant Analyze (Miltenyi Biotec, Bergisch Gladbach,
Germany). The mean fluorescence intensity (MFI) in the gated cell
population was measured (10 000 events per sample).
TEER Measurement of IPEC-J2 Monolayers. For the TEER
assay, IPEC-J2 cells (5 × 105 cells/well) were seeded to ThinCertTM
cell culture inserts (polyethylene terephthalate capillary pore
membranes; 0.4 μm pore size; Greiner BioOne, Frickenhausen,
Germany) compatible with 6-well plates. Cells were cultured for 7
days with medium exchange in the apical and basolateral side every
third day. The TEER was measured using an epithelial voltammeter
EVOM2 with a chopstick electrode STX2 (World Precision
Instruments Inc., Sarasota, FL, USA) and used as indicator for
confluency.54 When TEER of the cell monolayer reached values over
1 kΩ cm2 (day 7), the medium in the apical compartment was
changed to medium containing tested compounds or LSH at selected
concentrations or PBS as a control. At day 10, the TEER was
measured, and medium was once again exchanged to fresh medium
containing tested compounds or LSH. The medium in the basolateral
side was changed in parallel. At day 13, the TEER was measured, and
cells were washed twice with PBS and harvested to RNAlater (Qiagen
GmbH, Hilden, Germany) for qPCR analysis or lysed with cOmplete
Lysis-M (Roche, Basel, Switzerland) containing protease and
phosphatase inhibitor cocktail (Roche, Basel, Switzerland) for
Western blot analysis.
Western Blot Analysis. The cell lysate was centrifuged at 14 000
g for 15 min at 4 °C. The total protein concentration of the cell and
nuclear lysates were quantified with the BCA protein assay kit (Bio-
Rad, Hercules, CA, USA) using BSA as a standard. After equilibration
of protein concentration between the samples, the lysates were boiled
with 4xLaemmli Sample Buffer (Bio-Rad) and stored at −20 °C. The
protein lysates were separated by 10 or 12.5% SDS−PAGE and
transferred to nitrocellulose membrane Amersham Protran (Sigma-
Aldrich). The membrane was blocked with 5% skimmed milk powder
(Sigma-Aldrich) in Tris-buffered saline (Roth GmbH, Karlsruhe,
Germany) containing 0.1% (v/v) Tween 20 (SERVA) and then
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incubated overnight at 4 °C with primary rabbit monoclonal
antibodies, anti-Claudin 3, polyclonal (Thermo-Fisher, Waltham,
MA, USA), anti-ZO-1, polyclonal (Bioss Antibodies, Woburn, MA,
USA), antibeta Actin, polyclonal (Abcam, Cambridge, UK), and
mouse anti-Claudin 4, monoclonal (Thermo-Fisher). The membranes
were washed (three times) and incubated with the secondary
antibody at a dilution of 1:3000 (v/v). HRP-conjugated goat
antirabbit IgG antibody (Abcam) or antimouse IgG, HRP-linked
antibody (Cell Signaling Technology, Denver, MA, USA) was used as
a secondary antibody. The protein bands were detected with
SignalFire ECL Reagent (Cell Signaling Technology) and visualized
using PXi 4 Touch (SYNGENE, Frederick, MD, USA). The β-actin
was used as a loading control. The protein level was determined by
normalization to that of β-actin. Relative expression was determined
as the ratio of the intensity of the protein band to that of the
corresponding control band and finally represented as the fold
increase over the control group.
RNA Extraction and Reverse Transcription. The total cellular
RNA was extracted using NucleoSpin RNA Clean-up (Macherey-
Nagel, Düren, Germany) according to the manufacturer’s instructions.
RNA samples were treated with PureLink DNase (Invitrogen,
Carlsbad, CA, USA). The quality and quantity of isolated RNA was
evaluated using 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA). Total RNA was reversely transcribed to cDNA using
Superscript III reverse Transcriptase kit (Life Technologies, Carlsbad,
CA, USA) according to the manufacturers protocol.
Real Time qPCR Analysis. The levels of mRNA expression for
Claudin 3 (Cldn3), Claudin 4 (Cldn4), and Zona occludens-1 (ZO-
1) were quantified by Brilliant II SYBR Green QPCR Kit (Agilent
Technologies, Palo Alto, CA, USA) using Aria Mx Real-Time PCR
system (Agilent Technologies). For the qPCR experiments, the
following are primers against the sequences of porcine: Cldn3 (sense
= 5′-GCCAAGATCCTCTACTCCGC-3′, antisense = 5′-ATACG-
TAGTCCTTGCGGTCG-3′), Cldn4 (sense = 5′-CAACTGCGTG-
GATGATGAGA-3′, antisense = 5′- CCAGGGGATTGTA-
GAAGTCG-3′), ZO-1 (sense = 5′-ACAGTGCCCAGAGACCAA-
GA-3′, antisense = 5′-CATTTCCTCGGGGTAGGGGT-3′) and the
housekeeping genes β-actin (ACTB) (sense = 5′- CACCG-
CAAATGCTTCTAGGC-3′, antisense = 5′-TGCGCAAGT-
TAGGTTTTGTCA-3′), succinate dehydrogenase subunit A
(SDHA) (sense = 5′- CAAACTCGCTCCTGGACCTC-3′, antisense
= 5′-CCGGAGGATCTTCTCACAGC-3′), and β2-microglobulin
(β2-glob) (sense = 5′-CCCCGAAGGTTCAGGTTTAC-3′, antisense
= 5′-CGGCAGCTATACTGATCCAC-3′). The cycling conditions
were 95 °C for 10 min followed by 40 cycles of denaturing at 95 °C
for 15 s and annealing/extension for 1 min at 60 °C. The amount of
cDNA content of each gene in the tested sample was calculated based
on the respective calibration curve and normalized to β-actin cDNA
content.
Statistical Analysis. The data were analyzed using Statistica 13
software (StatSoft, Tulsa, OK, USA) or GraphPad Prism. For samples
with normal distribution, one-way analysis of variance followed by the
Tukey’s or Dunnet’s posthoc test was conducted. To compare
samples with distributions other than normal, nonparametric
Kruskal−Wallis one-way analysis of variance or nonparametric
Mann−Whitney test was performed. Associations between the
TEER and TJ protein production were determined using the
Spearman’s rank-order correlation analysis.
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